Aligos Therapeutics (ALGS) Competitors

Caribou Biosciences (NASDAQ:CRBU) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Is CRBU or ALGS more profitable?

Caribou Biosciences has a net margin of -1,800.93% compared to Aligos Therapeutics' net margin of -2,337.24%. Aligos Therapeutics' return on equity of -22.41% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,800.93%	-62.35%	-49.65%
Aligos Therapeutics	-2,337.24%	-22.41%	-12.09%

Which has better earnings and valuation, CRBU or ALGS?

Aligos Therapeutics has lower revenue, but higher earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$9.99M	17.57	-$149.10M	-$1.78	-1.06
Aligos Therapeutics	$3.94M	13.33	-$131.21M	-$19.79	-0.43

Do institutionals and insiders believe in CRBU or ALGS?

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 9.5% of Caribou Biosciences shares are held by insiders. Comparatively, 4.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media prefer CRBU or ALGS?

In the previous week, Caribou Biosciences had 15 more articles in the media than Aligos Therapeutics. MarketBeat recorded 21 mentions for Caribou Biosciences and 6 mentions for Aligos Therapeutics. Caribou Biosciences' average media sentiment score of 0.58 beat Aligos Therapeutics' score of 0.47 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caribou Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Aligos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, CRBU or ALGS?

Caribou Biosciences has a beta of 2.55, suggesting that its share price is 155% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.77, suggesting that its share price is 177% more volatile than the S&P 500.

Do analysts prefer CRBU or ALGS?

Caribou Biosciences presently has a consensus target price of $6.67, indicating a potential upside of 253.67%. Aligos Therapeutics has a consensus target price of $50.00, indicating a potential upside of 485.48%. Given Aligos Therapeutics' higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Caribou Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aligos Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Caribou Biosciences beats Aligos Therapeutics on 9 of the 15 factors compared between the two stocks.